Intensive Care Med. 2007 Mar;33(3):396-9. Epub 2007 Feb 15.

Increasing evidence that the risks of rhAPC may outweigh its benefits.

Eichacker PQ, Natanson C.

Comment in

Is there increasing evidence that the risks of rhAPC may outweigh its benefits? [Intensive Care Med. 2007]
Is there increasing evidence that the risks of rhAPC may outweigh its benefits?Plataki M, Vaporidi K, Georgopoulos D. Intensive Care Med. 2007 Aug; 33(8):1485-6; author reply 1489. Epub 2007 Jun 12.
Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. [Intensive Care Med. 2007]
Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions.Williams MD, Macias W, Rustige J. Intensive Care Med. 2007 Aug; 33(8):1487-8; author reply 1489-91. Epub 2007 Jun 12.

Comment on

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. [Intensive Care Med. 2007]
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Intensive Care Med. 2007 Mar; 33(3):426-34. Epub 2007 Feb 15.
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. [Intensive Care Med. 2007]
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.Kanji S, Perreault MM, Chant C, Williamson D, Burry L. Intensive Care Med. 2007 Mar; 33(3):517-23. Epub 2007 Feb 15.

PMID:: 17325833; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Risks and benefits of activated protein C treatment for severe sepsis. [N Engl J Med. 2002]
Risks and benefits of activated protein C treatment for severe sepsis.
Warren HS, Suffredini AF, Eichacker PQ, Munford RS. N Engl J Med. 2002 Sep 26; 347(13):1027-30.
Is there increasing evidence that the risks of rhAPC may outweigh its benefits? [Intensive Care Med. 2007]
Is there increasing evidence that the risks of rhAPC may outweigh its benefits?
Plataki M, Vaporidi K, Georgopoulos D. Intensive Care Med. 2007 Aug; 33(8):1485-6; author reply 1489. Epub 2007 Jun 12.
Recombinant human activated protein C, package labeling, and hemorrhage risks. [Crit Care Med. 2009]
Recombinant human activated protein C, package labeling, and hemorrhage risks.
Sweeney DA, Natanson C, Eichacker PQ. Crit Care Med. 2009 Jan; 37(1):327-9.
Review [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis]. [Ugeskr Laeger. 2004]
Review [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
Heslet L, Nielsen JD, Schierbeck J, Andersen JS. Ugeskr Laeger. 2004 Mar 8; 166(11):997-1002.
Review Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa. [Vasc Health Risk Manag. 2006]
Review Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
Rice TW. Vasc Health Risk Manag. 2006; 2(1):3-18.

See reviews... See all...

Cited by 10 PubMed Central articles

The late phase of sepsis is characterized by an increased microbiological burden and death rate. [Crit Care. 2011]
The late phase of sepsis is characterized by an increased microbiological burden and death rate.
Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC. Crit Care. 2011 Jul 28; 15(4):R183. Epub 2011 Jul 28.
Is There NO Treatment For Severe Sepsis? [Libyan J Med. 2008]
Is There NO Treatment For Severe Sepsis?
As B, A C. Libyan J Med. 2008 Mar 1; 3(1):34-8. Epub 2008 Mar 1.
APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. [Crit Care. 2010]
APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.
Pettilä V, Kyhälä L, Kylänpää ML, Leppäniemi A, Tallgren M, Markkola A, Puolakkainen P, Repo H, Kemppainen E. Crit Care. 2010; 14(4):R139. Epub 2010 Jul 27.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Increasing evidence that the risks of rhAPC may outweigh its benefits.
Increasing evidence that the risks of rhAPC may outweigh its benefits.
Intensive Care Med. 2007 Mar ;33(3):396-9. Epub 2007 Feb 15 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Increasing evidence that the risks of rhAPC may outweigh its benefits.

Comment in

Comment on

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 10 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information